Dimercaprol Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 100 mg/mL
Reference Brands: B.A.L (USA)
Category:
Critical Care
Dimercaprol is available in Injection
and strengths such as 100 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dimercaprol is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dimercaprol can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Dimercaprol, also known as British Anti-Lewisite (BAL), is a chelating agent widely used in the treatment of acute heavy metal poisoning. It is primarily indicated for poisoning caused by arsenic, mercury, gold, and severe lead exposure, and has also been used in cases involving antimony, thallium, and bismuth, although evidence for these uses is more limited. Dimercaprol is administered by deep intramuscular injection and is typically reserved for emergency and critical care situations due to its potent action and potential adverse effects.
For many years, dimercaprol has been a cornerstone of chelation therapy, particularly in cases of arsenic and lead poisoning, and it is recognized as an essential medicine. It is also an established antidote to the organometallic chemical warfare agent Lewisite. Because of its toxicity profile, safer oral chelating agents such as succimer have been developed; however, dimercaprol remains important in severe or life-threatening poisonings. Additionally, dimercaprol is approved for the treatment of Wilson’s disease, a genetic disorder characterized by excessive copper accumulation in the body, due to its ability to chelate copper. Experimental studies have also shown its potential to neutralize snake venom activity by binding zinc ions required for venom metalloproteinases.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing